- Home
- PALI vs EIC Comparison
PALI vs EIC Comparison
Compare PALI & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PALI | EIC |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.8M | 293.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PALI | EIC |
|---|---|---|
| Price | $1.92 | $11.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $17.67 | $14.00 |
| AVG Volume (30 Days) | ★ 5.8M | 275.8K |
| Earning Date | 11-10-2025 | 02-19-2026 |
| Dividend Yield | N/A | ★ 13.81% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.14 |
| Revenue | N/A | ★ $59,262,402.00 |
| Revenue This Year | N/A | $37.84 |
| Revenue Next Year | N/A | $23.33 |
| P/E Ratio | ★ N/A | $9.94 |
| Revenue Growth | N/A | ★ 44.30 |
| 52 Week Low | $0.53 | $10.81 |
| 52 Week High | $2.64 | $16.39 |
Technical Indicators
Market Signals| Indicator | PALI | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 47.33 | 41.33 |
| Support Level | $2.24 | $11.20 |
| Resistance Level | $2.55 | $11.60 |
| Average True Range (ATR) | 0.20 | 0.22 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 31.82 | 42.86 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.